Novel Bacillus anthracis Lysin for Rapid Diagnostic Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bacillus anthracis and related bacteria exhibit high resistance to lytic enzymes due to peptidoglycan modifications, making it challenging to develop effective methods for rapid identification and lysis.
Innovation Solution
Development of novel peptidoglycan hydrolase lytic enzymes, such as BQ22, which are identified through in-silico methods and tested for activity against Bacillus anthracis using turbidity reduction assays, and used in conjunction with molecular diagnostic tests for rapid identification and lysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lytic enzymes (lysozyme, mutanolysin) are used against Bacillus anthracis, then the cell wall structure is targeted, but high resistance is observed due to peptidoglycan modifications (92% N-deacylation of GlcNAc residues and high cross-linkage)
Solution Approach 1:
The patent applies parameter changes by modifying the enzymatic activity parameters to match the modified peptidoglycan structure. Specifically, the lysin enzyme is engineered to recognize and cleave N-deacetylated GlcNAc residues (the modified form present in 92% of B. anthracis peptidoglycan) rather than the standard N-acetylated form. This parameter change in substrate specificity overcomes the resistance mechanism while maintaining reliable lysis effectiveness.
2Loss of time
If rapid identification and lysis of Bacillus anthracis is achieved using novel lysins, then diagnostic speed is improved, but development complexity increases due to need for in-silico screening and activity testing
Solution Approach 1:
The patent applies preliminary action by performing in-silico screening and characterization of candidate lysins before actual diagnostic application. The computational modeling and preliminary in-vitro activity testing identify promising enzyme candidates in advance, allowing optimization of lysis conditions and ensuring effectiveness before deployment in rapid diagnostic protocols. This preliminary work reduces the time required during actual diagnosis while managing development complexity through systematic pre-screening.
3Strength
If peptidoglycan cross-linkage is increased in Bacillus anthracis, then cell wall strength is improved, but resistance to lytic enzymes increases
Solution Approach 1:
The patent applies local quality by targeting specific local regions of the peptidoglycan structure that differ from conventional bacteria. The lysin enzyme is designed to recognize and bind to the specific local configuration of N-deacetylated GlcNAc residues and the particular cross-linkage pattern (A1γ type) found in B. anthracis. This localized specificity allows the enzyme to effectively cleave bonds in these modified regions without being hindered by the overall increased cross-linkage density, thereby maintaining reliable lysis activity despite enhanced cell wall strength.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel peptidoglycan hydrolases demonstrate high activity against Bacillus anthracis, enabling rapid and effective lysis and identification, facilitating improved diagnostic and decontamination processes.
Implementation Method 1
Peptidoglycan hydrolases are a diverse group of enzymes that cleave the cell wall at specific structural sites and are responsible for the highly-regulated cleavage of peptidoglycan during cell growth and division
Implementation Method 2
screen the identified lysins for usage conditions are described. One or more lytic peptides having high activity against the intact Bacillus anthracis cell wall through the design and implementation of a turbidity reduction assay
Data Source
AI summary
Disclosed herein are the identification, cloning, and optimizing the lytic activity of one or more novel Bacillus lysin proteins, a method of selecting a lysin agent for use in molecular diagnostic testing that includes analyzing genome databases for Bacillus anthracis and near neighbors, selecting candidate genes encoding potential lytic enzymes based on conserved amino acid motifs as determined in peptidoglycan hydrolases, cloning the candidate genes in expression vector, isolating proteins thereof, and testing for lytic activity against Bacillus anthracis, and selecting an optimum gene of the candidate genes for optimizing lysis conditions.